DICLOFENAC /50 mg Tablet

Ornisid film tablets belong to the category of antibacterial/ antiviral drugs It is used for anti-protozoals Form: film coated tablets Active substances: ornidazole 250 mg/ tabl Package type: 20 tablets in blister Licensor: abdi ibrahim ilaç

Ornisid vaginal tablets belong to the category of antibacterial/ antiviral drugs It is used for anti-protozoals Form: vaginal tablets Active substances: ornidazole Package type: 3 tablets in blister Licensor: abdi ibrahim ilaç

Oroheks % 02 oral sprey belongs to the respiratory system category It is used for antiseptic Form: oral sprey Active substances: 02% chlorhexidine gluconate Package type: 30 ml glass bottle with oral applicator Licensor: tripharma

Oroheks %02 gargle 200 ml belongs to the respiratory system category It is used for antiseptic Form: gargle Active substances: 02% chlorhexidine gluconate Package type: 200 ml glass bottle; 15 ml measurement cap Licensor: abdi ibrahim ilaç

Oroheks plus oral sprey belongs to the respiratory system category It is used for antiinflammatory, antiseptic Form: oral sprey Active substances: 0,15 % benzydamine hcl, 0,12 % klorhexidine gluconate Package type: 30 ml glass bottle with oral applicator Licensor: tripharma

Osteomax tablet 70 mg belongs to the endocrine and metabolism category It is used for bone calcium regulators Form: tablets Active substances: alendronate sodium 9135 mg/ tablet Package type: alu/alu blister packs of 4 tablets Licensor: abdi ibrahim ilaç

Platelet aggregation inhibitors (COX inhibitors)

Atypical Antipsychotics - Schizophrenia

Adrenergics (B2 agonists) in combination with corticosteroids - Asthma & COPD

Thyroid Preparations - Hypothyroidism

Antiepileptic

NSAID

Abdi İbrahim has been awarded the 'Equal Opportunity Model' (FEM) certificate, developed by KAGIDER with the technical support of the World Bank, to promote gender equality in business life and enhance women's productivity. Deniz Daver, President of Human and Culture Group, expressed their happiness in receiving this certificate, stating, “This certificate, which acknowledges companies' sensitive approaches to gender equality and women's empowerment in employment, is an important indicator reflecting Abdi İbrahim's vision of inclusiveness. We see FEM certificate as a reward for our determined and continuous efforts in this field.

Turkish pharmaceutical industry leader Abdi Ibrahim s journey began in 1912.In addition to its partnerships with more than 30 licensing firms across the globe, Abdi Ibrahim develops its own products with 250 brands and 500 products.Abdi Ibrahim has subsidiaries operating in 17 countries outside Turkey, exports to more than 70 countries from the European Union to Canada, North Africa to Asia and generates the highest employment rate in the Turkish pharmaceutical industry with 5500 qualified employees.

Abdi İbrahim, the uninterrupted leader of the Turkish pharmaceutical industry for 21 years, received awards in 5 categories at the Crystal Mortar Awards organized by the Chemists' Association.

 Acting for 111 years with the mission of improving life, Abdi İbrahim received awards in 5 categories at the Crystal Mortar Awards, given within the scope of the 11th International Pharmaceutical Chemistry Congress for its R&D studies and investments. On the opening day of the 11th International Pharmaceutical Chemistry Congress organized by the Chemists' Association in Antalya this year, the R&D activities of pharmaceutical companies were awarded in 7 categories. Abdi İbrahim won awards in 5 categories, including the “Pharmaceutical Company with the Most R&D Investments” category.

Providing accommodation for children and their families who come to Istanbul for cancer treatment

Abdi İbrahim, the leader of the Turkish pharmaceutical industry, has initiated a social project for children undergoing cancer treatment and their families. Abdi İbrahim Foundation House of Kindness, which provides accommodation for children who come to İstanbul for cancer treatment but face difficulties staying due to economic reasons, has opened its doors in Fatih, İstanbul. Speaking at the opening ceremony, Nesrin Barut Esirtgen, Deputy Chairperson of Abdi İbrahim and Chairperson of the Board of Trustees of the Abdi İbrahim Foundation, said: “Taking into account the accommodation needs of our children and their relatives who come to Istanbul for treatment, we realized the House of Kindness project to be part of the solution. We strongly believe that kindness and the passion for healing are contagious. Our House of Kindness is a reflection of this belief and will.” D...

The Sterile Inhalation Facility, jointly developed by Abdi İbrahim and GSK Türkiye in collaboration with the Investment Office of the Presidency of the Republic of Türkiye, commences operations.

The facility, built with an investment of TRY 340 million, will enable Türkiye to benefit from the advanced ‘nebule’ technology, which is used in the treatment of respiratory diseases. The facility is the first in the world capable of manufacturing the complete range of GSK’s nebule portfolio.

ANOTHER FIRST FROM ABDİ İBRAHİM

Abdi İbrahim, the leader in the Turkish pharmaceutical industry for 21 years, continues its unwavering commitment to investing in biotechnology. Abdi İbrahim has announced a technology transfer agreement with the Spanish biosimilar developer, mAbxience, which is among the world’s leading companies in the field.

Accordingly, a currently imported cancer drug will now be manufactured by AbdiBio. Nezih Barut, Chairman of Abdi İbrahim, noted the technology transfer’s significance as the first “cell-to-end product” biotech pharmaceutical in Türkiye.

ABDİ İBRAHİM STRIKES DEAL WITH ARONPHARMA

Abdi İbrahim, Türkiye's leading pharmaceutical company and a strong player in consumer health products, is collaborating with Aronpharma, a key European company specializing in innovative food supplements for their innovative brand Berroxin.

Abdi İbrahim has acquired sales and distribution rights in Türkiye for products that help support the immune system under the Berroxin brand of Aronpharma, which offers innovative food supplement products. The portfolio will be launched in the Turkish market starting in 2023 with the assurance of Abdi İbrahim.

The unrivalled leader in the Turkish pharmaceutical industry for 22 years, Abdi İbrahim attains a noteworthy achievement by earning a coveted spot on the Climate A list within the 2023 Carbon Disclosure Project (CDP) Climate Change Program. For 112 years marked by a passion for progress, Abdi İbrahim has actively embraced the green transformation by diligently integrating environmental considerations into its business models. Aligned with the ambitious 1.5°C target of the Paris Agreement, its greenhouse gas emission reduction targets boast the validation of the Science Based Targets Initiative (SBTi). Aligned with this target, the Company is resolutely aiming to curtail its Scope 1 and Scope 2 greenhouse gas emissions by 60 percent, and its Scope 3 emissions by 45 percent by 2030, measured against the baseline year 2020. 

Established in 2021 by Abdi İbrahim, the healing power of Türkiye, the Abdi İbrahim Foundation aims to impart swimming skills to children aged 5 to 8 with Down Syndrome through the social responsibility project, Brave Strokes. This initiative is realized in collaboration with the Down Syndrome Association of Türkiye.

Abdi İbrahim, the undisputed leader of the Turkish pharmaceutical industry for 22 years, has initiated a new project under the Abdi İbrahim Foundation, as part of its social investment programs that aim to create value for the country and society by healing the lives it touches.

Conducting its sustainability operations with the vision of “Healing the Future,” Abdi İbrahim has released its 6th Sustainability Report, covering the period of 2021-2022. The report includes Abdi İbrahim’s sustainability goals set for 2030, 2040, and 2050, within the framework of healing the future of the ecosystem, people and business, along with the projects carried out in line with these goals. Abdi İbrahim’s sustainability report offers a unique reading experience with digital artworks designed by artist Bager Akbay and his team, combining human imagination with artificial intelligence.

Planning its sustainability activities with a comprehensive perspective encompassing environmental, social, and governance aspects, Abdi İbrahim published its 6th Sustainability Report, detailing its sustainability efforts between January 1, 2021 and December 31, 2022. 

Abdi İbrahim forms a joint venture with Saudi Cigalah Healthcare, laying the foundation for expansion into Saudi Arabia and beyond, prioritizing exports as the initial step.

Abdi İbrahim extends its healing touch to the Gulf

Abdi İbrahim and CorPal unite to advance digital health

As the unrivaled leader of the Turkish pharmaceutical industry for 22 years, Abdi İbrahim seeks to maximize the advantages of digital health solutions for both patients and healthcare professionals through a comprehensive partnership with CorPal, an AI-supported holistic rehabilitation platform. Through this collaboration, patients requiring long-term follow-up can access mental and physical rehabilitation anytime and anywhere.

Abdi İbrahim, the healing power of Türkiye, has made a pioneering move in digital health through its collaboration with CorPal, an AI-supported holistic rehabilitation platform. Strengthening Abdi İbrahim's value-driven approach in the pharmaceutical industry and its technological leadership, this collaboration aims to develop innovative treatments, expand healthcare services, and provide solutions to help physicians improve patient care and monitoring.